Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Washington: Department of Health and Human Services. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 14 May 2019
2.
RossettiBMontagnaniFDe LucaA.Current and emerging two-drug approaches for HIV-1 therapy in ART-naïve and ART-experienced, virologically suppressed patients. Expert Opin Pharmacother2018;
19: 713–738.
3.
NavarroJSantosJRSilvaA, et al. Effectiveness of once-daily dolutegravir plus boosted darunavir as a switch strategy in human immunodeficiency virus-infected, heavily treated patients. Pharmacotherapy2019;
39: 501–507.
4.
CapettiAFCossuMVOrofinoG, et al.
A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks’ observational data. BMC Infect Dis2017;
17: 658.
5.
De La FuenteSGutierrezAGomezA, et al. Dual therapy with dolutegravir plus darunavir/cobicistat as salvage therapy regimen. Results at 24 weeks. Poster session presented at: International AIDS Society 2017; 23–26 July 2017; France, Paris.
6.
LeeSAKimSWChangHH, et al.
Effectiveness, safety, and tolerability of a switch to dual therapy with dolutegravir plus cobicistat-boosted darunavir in treatment-experienced patients with human immunodeficiency virus. Infect Chemother2018;
50: 252–262.
7.
WheelerJChanSHarriganPR, et al.
Dolutegravir with boosted darunavir treatment simplification for the transmitted HIV thymidine analog resistance in Manitoba, Canada. Int J STD AIDS2018;
29: 520–522.
8.
RaffiFJaegerHQuiros-RoldanE, et al.
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis2013;
13: 927–935.
9.
TremblayCL.Combating HIV resistance – focus on darunavir. Ther Clin Risk Manag2008;
4: 759–766.
